List of Excipients in Branded Drug ASENAPINE MALEATE
Generic Drugs Containing ASENAPINE MALEATE
What are the Most Frequently-Used Excipients in ASENAPINE MALEATE?
| # Of NDCs | Excipient |
|---|---|
| 1 | ASPARTAME |
| 1 | CELLULOSE, MICROCRYSTALLINE |
| 1 | CROSPOVIDONE |
| 1 | LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE |
| 1 | MAGNESIUM STEARATE |
| 1 | POVIDONE K30 |
| 1 | SILICON DIOXIDE |
| ># Of NDCs | >Excipient |
Asenapine Maleate Excipient Strategy and Commercial Opportunities
Asenapine maleate has two FDA-approved dosage forms: Saphris sublingual tablets and Secuado transdermal systems. The most attractive excipient opportunities are in taste management, rapid oral disintegration, moisture control, transdermal adhesive systems, and differentiated 505(b)(2) products. Generic competition limits the value of undifferentiated tablet excipients, while transdermal formulation know-how and performance-critical excipients offer stronger commercial protection.
What dosage forms and excipient systems are used for asenapine maleate?
Asenapine maleate is a small-molecule atypical antipsychotic. FDA-approved products use two different delivery platforms:
| Product | Dosage form | FDA approval | Active ingredient | Primary excipient opportunity |
|---|---|---|---|---|
| Saphris | Sublingual tablet | 2009 | Asenapine maleate | Fast disintegration, taste management, low-moisture processing |
| Secuado | Transdermal system | 2019 | Asenapine | Adhesive matrix, controlled release, skin adhesion and tolerability |
Saphris is approved for schizophrenia in adults and for acute treatment of manic or mixed episodes associated with bipolar I disorder in adults and pediatric patients aged 10 years and older. Secuado is approved for the treatment of schizophrenia in adults.[1,2]
Asenapine is administered sublingually because conventional swallowing presents significant bioavailability limitations. The sublingual product must dissolve rapidly in saliva and deliver drug through the oral mucosa. The transdermal product avoids gastrointestinal administration and provides continuous drug delivery over 24 hours.
What excipients are used in Saphris sublingual tablets?
Saphris uses a compact sublingual formulation containing mannitol, gelatin, aspartame, and mineral or alkaline processing components identified in the FDA-approved labeling.[1] The formulation is designed to dissolve under the tongue rather than function as a conventional swallowed tablet.
The principal excipient functions are:
| Excipient function | Strategic objective |
|---|---|
| Bulking and mouthfeel | Provide adequate tablet mass and a tolerable oral texture |
| Rapid disintegration | Release asenapine quickly in a limited saliva volume |
| Binder or film-forming support | Maintain tablet integrity during packaging and handling |
| Sweetening and taste correction | Reduce bitterness and improve patient acceptability |
| pH adjustment | Support drug dissolution and formulation stability |
| Moisture control | Prevent premature softening, degradation, or packaging failure |
Mannitol is commercially important because it provides a relatively clean mouthfeel and is widely used in orally disintegrating and sublingual products. Direct-compression grades, spray-dried grades, and co-processed mannitol systems can compete on flow, compactability, disintegration time, and sensory performance.
Gelatin can support tablet structure and rapid dissolution. It also creates formulation constraints involving animal origin, religious certification, allergen policies, and supply-chain qualification. Vegetarian or synthetic alternatives may create a differentiated excipient platform, but substitution requires comparative testing for tensile strength, disintegration, friability, dissolution, and taste.
Aspartame provides sweetness but creates a phenylalanine labeling requirement. An alternative sweetener system could address patients who avoid aspartame, although any substitution would require reformulation work and new stability and bioequivalence data.
What excipient technologies can improve sublingual asenapine products?
The highest-value opportunities are performance-based rather than commodity-based.
Taste masking
Asenapine has an intense bitter taste. A supplier that can reduce bitterness without delaying mucosal dissolution could support:
- improved adherence;
- pediatric acceptability;
- lower reliance on aspartame;
- reduced need for flavor loading;
- differentiated line extensions.
Potential approaches include ion-pairing, polymeric taste masking, cyclodextrin complexation, lipid-based masking, coated microparticles, and pH-modifying systems. The main development risk is that a coating or complex that suppresses bitterness may also reduce the fraction of drug available for sublingual absorption.
Rapid-dissolve excipients
Commercially useful candidates include engineered mannitol, low-substituted hydroxypropyl cellulose, crospovidone, co-processed excipients, and specialized binders. The target is not simply rapid disintegration. The formulation must also maintain:
- acceptable tablet hardness;
- low friability;
- minimal residue under the tongue;
- consistent content uniformity;
- low hygroscopicity;
- reproducible dissolution in small saliva volumes.
A sublingual tablet that disintegrates rapidly but produces a gritty or sticky residue is unlikely to improve the product.
Moisture-barrier systems
Sublingual tablets are sensitive to humidity and mechanical damage. High-value packaging and excipient opportunities include:
- low-moisture excipient grades;
- desiccant-integrated blister systems;
- high-barrier foil laminates;
- unit-dose child-resistant packaging;
- improved tablet ejection and handling characteristics.
Packaging is part of the commercial excipient strategy because the tablet is exposed to moisture during manufacturing, storage, dispensing, and patient use.
What excipients and technologies are used in Secuado transdermal systems?
Secuado uses an adhesive matrix transdermal system. The patch incorporates a backing layer, a drug-containing adhesive matrix, and a release liner.[2] The product delivers asenapine over 24 hours at four nominal strengths: 3.8, 5.7, 7.6, and 11.4 mg per 24 hours.
The critical excipient and component functions are:
| System component | Performance requirement |
|---|---|
| Pressure-sensitive adhesive | Maintain skin contact for 24 hours |
| Drug matrix | Dissolve and release asenapine consistently |
| Backing layer | Protect the matrix and control environmental exposure |
| Release liner | Permit clean application without damaging the adhesive |
| Permeation-control system | Regulate drug movement into and through skin |
Transdermal excipients have greater formulation specificity than standard tablet excipients. A replacement adhesive can affect drug solubility, crystallization, skin flux, tack, peel, irritation, residue, cold flow, and storage stability. These interactions make transdermal excipient substitution more difficult than ordinary generic tablet reformulation.
What commercial opportunities exist for asenapine excipient suppliers?
Generic sublingual tablets
The largest near-term opportunity is supply to manufacturers of generic asenapine sublingual tablets. Generic developers can compete through:
- direct-compression excipient platforms;
- non-aspartame sweetener systems;
- improved taste masking;
- lower-cost blister packaging;
- robust moisture protection;
- excipient systems that simplify scale-up.
The opportunity is volume-driven and price-sensitive. Commodity mannitol, gelatin, sweeteners, and lubricants face strong substitution risk. Suppliers with compendial grades, global regulatory files, and validated supply continuity have a stronger position than suppliers offering only standard materials.
Pediatric and adherence-oriented products
Asenapine has pediatric bipolar I indications for Saphris, creating a potential niche for more acceptable taste and mouthfeel. Pediatric formulations may support premium positioning if they improve administration without changing the approved route or exposure profile.
Potential products include:
- flavored sublingual tablets;
- lower-residue tablets;
- smaller unit doses;
- packaging optimized for supervised administration;
- excipient systems that reduce bitterness without increasing disintegration time.
Any pediatric reformulation must address accidental ingestion, sweetener exposure, labeling, dose flexibility, and palatability evidence.
Transdermal line extensions
The transdermal route offers a platform for 505(b)(2) development. Potential commercial concepts include:
- alternative patch sizes;
- longer-wear systems;
- lower-irritation adhesive matrices;
- improved adhesion during bathing or exercise;
- reduced visible residue;
- easier application and removal;
- alternative backing and liner materials.
A new product would need a clear clinical or adherence advantage. A simple excipient substitution is unlikely to justify a premium unless it materially improves skin tolerability, adhesion, wear time, or pharmacokinetic consistency.
Regional licensing and contract development
Asenapine formulation know-how can be licensed to regional pharmaceutical companies seeking differentiated products without building internal transdermal or sublingual development capability. The most licensable assets are likely to be:
- validated taste-masking technology;
- proprietary adhesive matrices;
- low-irritation transdermal systems;
- platform technologies that support multiple antipsychotics;
- manufacturing processes that reduce coating, drying, or packaging costs.
Licensing value increases when the formulation is supported by human pharmacokinetic data, comparative adhesion data, stability data, and freedom-to-operate analysis.
What regulatory requirements apply to asenapine excipient changes?
For generic sublingual tablets, the applicable pathway is generally an abbreviated new drug application. The product must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug, subject to FDA requirements for the specific dosage form.[3]
Excipient changes can affect:
- drug release;
- local oral exposure;
- systemic bioavailability;
- tablet disintegration;
- taste and patient administration;
- impurity formation;
- stability;
- content uniformity.
The FDA Inactive Ingredient Database can support the selection of previously used excipients and route-specific precedent. It does not automatically establish acceptability for a new concentration, route, dosage form, or patient population.[4]
For transdermal products, the development burden is higher. The sponsor must characterize adhesion, irritation, sensitization, drug release, permeation, residual drug, dose dumping risk, and manufacturing uniformity. Adhesive changes may require extensive comparative clinical or pharmacokinetic evidence.
Novel excipients can provide differentiation but carry higher regulatory risk. A supplier seeking to commercialize a new excipient should build a toxicology package, manufacturing-control strategy, impurity profile, and route-specific safety justification.
How strong is the patent estate for asenapine excipient opportunities?
The strongest protection generally arises from claims directed to:
- specific transdermal adhesive compositions;
- controlled-release matrices;
- drug-to-excipient ratios;
- permeation-enhancing systems;
- defined patch architectures;
- manufacturing processes;
- specific dosage regimens or methods of use.
Broad claims to common excipients such as mannitol, gelatin, or standard sweeteners are unlikely to provide durable protection because these materials are widely used and often disclosed in prior art.
For generic sublingual products, the primary legal issues are likely to involve Orange Book-listed patents, formulation claims, method-of-use claims, and regulatory exclusivity. Paragraph IV certification can trigger patent litigation if an ANDA applicant asserts that listed patents are invalid, unenforceable, or not infringed.[5]
For Secuado, formulation and transdermal-system patents are more commercially relevant than conventional tablet patents. The patent risk depends on claim scope, expiration dates, terminal disclaimers, pediatric extensions, and whether a proposed patch can avoid the claimed adhesive or delivery architecture.
Patent diligence should distinguish:
- active ingredient patents;
- sublingual formulation patents;
- transdermal formulation patents;
- method-of-use patents;
- manufacturing patents;
- Orange Book-listed patents;
- unlisted platform or trade-secret know-how.
When does asenapine lose exclusivity and what generic entry risks exist?
Saphris entered the U.S. market in 2009, while Secuado was approved in 2019. FDA marketing exclusivity and patent protection are separate. Loss of exclusivity does not eliminate formulation barriers, manufacturing complexity, or litigation risk.
| Risk category | Sublingual tablet | Transdermal patch |
|---|---|---|
| Generic development cost | Moderate | High |
| Bioequivalence complexity | Moderate to high | High |
| Excipient substitution risk | Taste and dissolution | Adhesion, permeation, irritation |
| Manufacturing barrier | Tablet compression and packaging | Coating, drying, lamination, die-cutting |
| Patent sensitivity | Formulation and use claims | Adhesive and delivery-system claims |
| Commercial competition | Likely price-driven | More limited, potentially differentiated |
The most plausible generic launch scenario is a low-cost sublingual tablet using a substantially equivalent excipient system. Transdermal entry is less likely to occur through a simple substitution because the product is technically more difficult to reproduce and may require a more extensive regulatory package.
How does asenapine compare with competing antipsychotic delivery systems?
| Drug or platform | Route | Excipient opportunity | Competitive constraint |
|---|---|---|---|
| Asenapine | Sublingual | Taste masking and rapid disintegration | Small market and bitter taste |
| Asenapine | Transdermal | Adhesive matrix and skin tolerability | Complex development and manufacturing |
| Risperidone ODT | Oral disintegrating | Mouthfeel and taste | Established generic competition |
| Olanzapine ODT | Oral disintegrating | Rapid dissolution and taste | Broad generic availability |
| Aripiprazole oral products | Oral | Conventional solid-dose optimization | Multiple generic formulations |
| Long-acting injectable antipsychotics | Depot injection | Suspension, viscosity, and syringeability | Higher clinical and manufacturing barriers |
Asenapine’s differentiator is route of administration. The sublingual product addresses patients who have difficulty swallowing or may conceal medication in food, while the patch addresses adherence and gastrointestinal administration concerns. The commercial opportunity depends on whether excipient improvements translate into better use, not merely a lower cost of goods.
What is the revenue exposure and commercial outlook?
Asenapine is a mature branded and generic opportunity rather than a high-growth active pharmaceutical ingredient market. Revenue exposure is concentrated in:
- generic sublingual tablets;
- branded or licensed transdermal systems;
- specialty psychiatric products;
- excipient supply contracts;
- regional formulation licensing.
The most defensible commercial strategy is to sell a validated formulation solution rather than an individual excipient. A supplier offering a complete sublingual system or transdermal adhesive platform can capture more value, support regulatory submissions, and create switching costs.
Key Takeaways
- Asenapine maleate has two FDA-approved platforms: sublingual tablets and transdermal patches.
- Sublingual opportunities center on taste masking, rapid dissolution, low moisture, and non-aspartame systems.
- Transdermal opportunities center on adhesive performance, skin tolerability, drug crystallization control, and 24-hour wear.
- Commodity excipients face price pressure from generic manufacturers.
- Proprietary excipient combinations, validated processing methods, and formulation know-how offer stronger commercial protection.
- Generic sublingual entry is technically feasible and likely to be price-sensitive.
- Transdermal entry has higher formulation, manufacturing, regulatory, and patent barriers.
- Asenapine is a small molecule, so biosimilar risk does not apply. The relevant competition is generic and 505(b)(2) development.
- Patent diligence should focus on Orange Book-listed patents, transdermal formulation claims, method-of-use claims, and manufacturing patents.
- The strongest licensing opportunities involve complete delivery platforms supported by comparative performance and regulatory data.
FAQs
Can mannitol be replaced in an asenapine sublingual tablet?
Yes, but the replacement must preserve tablet strength, rapid disintegration, mouthfeel, dissolution, stability, and bioequivalence. A change from mannitol to another filler is not automatically low risk.
Is a transdermal asenapine product eligible for an ANDA?
A product that is pharmaceutically equivalent to the reference transdermal system may be considered under an ANDA, but transdermal equivalence requirements can be complex. A materially different delivery system may require a 505(b)(2) application.
What is the most valuable excipient innovation for asenapine?
A taste-masking system that preserves rapid sublingual absorption has the clearest near-term opportunity. For Secuado, a low-irritation adhesive that maintains 24-hour adhesion offers greater technical differentiation.
Does asenapine have biosimilar competition?
No. Asenapine is a chemically synthesized small molecule. Competition is expected through generic applications, branded reformulations, and 505(b)(2) products rather than biosimilar applications.
Can an excipient supplier obtain patent protection for an asenapine formulation?
Yes. Protection may be available for a novel composition, specific excipient ratio, adhesive matrix, manufacturing process, release profile, or defined performance parameter. A patent on a common excipient alone is generally less defensible than a claim tied to the complete asenapine delivery system.
References
- U.S. Food and Drug Administration. (2024). Saphris (asenapine) sublingual tablets: Prescribing information.
- U.S. Food and Drug Administration. (2024). Secuado (asenapine) transdermal system: Prescribing information.
- U.S. Food and Drug Administration. (2024). Draft guidance on asenapine maleate sublingual tablets.
- U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
- U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary.
- International Council for Harmonisation. (2023). ICH Q8(R2): Pharmaceutical development.
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
Visit the Subscription Options page for details on plans and pricing.
ISSN: 2162-2639

Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Access the Complete Database
Deeper Knowledge, Faster
- Analyze global market entry opportunities
- Obtain formulation and manufacturing information
- Drug patents in 130+ countries